
Prostate Cancer
Latest News
Latest Videos

More News

From the state of the “Tiger King’s” Joe Exotic’s prostate cancer to the emotional reunion of two 3-year-old cancer survivors, here’s what’s happening in the cancer landscape this week.

Our first imperative as cancer survivors is to travel on a journey of wellness and peace of mind, not fear and stress.

Articles containing misinformation on social media sites like Facebook and Twitter were more likely to be shared and liked than those with accurate information.

A survivor of prostate cancer celebrates the news that his cancer has not spread and describes how remission has made him feel.

Despite this “obesity paradox,” doctors do not recommend gaining weight with hopes of improving cancer outcomes.

The disease, which advanced to his spine and bones, prevented him from appearing onstage for the “Friends” reunion.

Reaching a younger age group of African American men for prostate cancer detection may improve their survival outcomes, says an expert from the University of California San Diego.

The treatment was also associated with antitumor activity in patients with metastatic castration-resistant prostate cancer.

Patients with nonmetastatic castration-resistant prostate cancer continued to tolerate long-term treatment with Nubeqa, allowing them to maintain their quality of life and remain on therapy.

The data, according to one of the study’s authors, are critical in understanding the disparities in prostate cancer.

The addition of an investigational therapy to standard-of-care treatment was associated with a median overall survival of 15.3 months in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

The PET imaging agent targets prostate-specific membrane antigen levels, which can improve the detection of suspected disease spread or recurrence compared with standard approaches.

Increased Screening Associated with Improved Outcomes in Younger Black Patients with Prostate Cancer
The study results lend strength to discuss prostate cancer screening in younger Black men, according to an expert.

From Al Roker’s cancer screening advice to the death of actor Charles Grodin, here’s what’s happening in the cancer landscape this week.

In this episode of the “CURE® Talks Cancer” podcast, Leanne Burnham, Ph.D., discusses the research she’s working on to address health disparities in Black men with prostate cancer after being inspired by her father’s diagnosis, and shares her own cancer survival story.

A recent analysis of veterans with prostate cancer showed that they are not being assessed and treated for cardiovascular risk factors at the rate they should be to optimize survival, particularly when being treated with androgen deprivation therapy, which has been associated with increased risk for cardiovascular disease.

A prostate cancer survivor recalls a time when the cancer center’s staff helped him realize that its OK to have fun while receiving cancer treatment.

Never say to someone that at least they have a “good” kind of cancer or that they don’t really look that sick, writes one cancer survivor.

The Food and Drug Administration’s recent approval of the first oral hormone therapy, Orgovyx, for the treatment of advanced prostate cancer has positioned the drug to become a standard of care for patients, according to an expert.

A survivor takes a closer look at the trouble with using the phrase “cancer-free” when discussing the disease with friends and family.

Here is a list of some recent trials that launched within the cancer space in February.

“Did you hear the one about the cancer procedure that went terribly wrong?” “It turned out to be a ‘bi-oopsie!’”

The combination of Erleada, Zytiga and the steroid prednisone was associated with a trend toward better survival outcomes in certain patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

Instead of buying your sweetheart chocolates for Valentine’s Day this year, one cancer survivor suggests people get screened as a gift to their significant other.

Patients with prostate cancer experienced no significant difference in quality of life when treated with two different types of radiation regimens, recent research has found.